Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL

Autor: Joana Diamond, Maria Gomes da Silva

Publikováno v: Acta Médica Portuguesa, Vol 26, Iss 4 (2013)

Os doentes com leucemia mielóide crónica em fase crónica, tratados com imatinib mesilato obtêm na maioria dos casos uma resposta clínica. Contudo, nem todos atingem uma resposta óptima ao imatinib mesilato, ou sequer aos mais potentes inibidore

Externí odkaz: https://doaj.org/article/d9fff250e42a42ec8db3adb8ce29fe7c

Negative MR

Autor: Nuno, Cerveira, Joana, Diamond, Sónia, Matos, Maria L, Amorim, Margarida, Coucelo, Susana, Bizarro, Ana Teresa, Simões, Francesca, Pierdomenico, Mariana, Lopes, Letícia, Ribeiro, Maria, do Carmo-Fonseca, José E, Guimarães, António, Almeida, Manuel R, Teixeira

Publikováno v: British journal of haematology. 186(6)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::67215d911e59ceefc100bb0253aba143
https://pubmed.ncbi.nlm.nih.gov/31218669

CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene

Autor: Manuel Maria de Sousa Ferreira Abecasis, Joana Diamond, José Cabeçadas, Hélio Belo, Antonio Almeida, Manuela Paula Guerra Pinheiro Gameiro da Costa

Publikováno v: Annals of Hematology. 95:2101-2104

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54740145c90c6d96e11e4d9f7347ce36
https://doi.org/10.1007/s00277-016-2827-3

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Autor: José Luís Passos-Coelho, Lara Neto, Elsa Teixeira, Helena Correia, Manuel Ribeiro, Ana Miranda, Joana Diamond, S. Santos, Ana Rita Marques

Publikováno v: Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, Springer Verlag, 2008, 114 (2), pp.223-232. ⟨10.1007/s10549-008-0002-9⟩

Introduction Human mammaglobin (hMAM) mRNA is a sensitive and specific marker of breast cancer cells. We evaluated if hMAM mRNA detection in serial peripheral blood samples from non-metastatic breast cancer patients predicts for disease recurrence. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75b3362397f2dd3bc0530fba4bfa1024
https://doi.org/10.1007/s10549-008-0002-9

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Autor: Kimmo Porkka, Katerina Machova Polakova, Jeroen Janssen, Johan Richter, Veli Kairisto, Satu Mustjoki, Francois-Xavier Mahon, Panayiotis Panayiotidis, Susanne Sauβele, Hans Ehrencrona, Henrik Hjorth-Hansen, Joelle Guilhot, Marc G. Berger, Antonio Almeida, Markus Pfirrmann, Joana Diamond, Martin Müller, Ulla Olsson-Strömberg, Andreas Hochhaus, Jiri Mayer

Publikováno v: University of Helsinki

Introduction: With imatinib (IM), 60% of patients with chronic myeloid leukemia (CML) achieved deep molecular responses (MR4: at least a 4-log reduction in BCR-ABL1 transcript level according to the International Scale) within 4 years (Hehlmann 2014)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b78d102bc4c2c916b0eb1a3abeb6cf67
https://doi.org/10.1182/blood.v128.22.789.789